News in numbers Trials per year globally, 1999–2022 744,100


Trials by health catagory Number of unclassifi ed trials: 122,365 (16.44%)


23,738 92,285 2,408 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Trials by year and WHO region, 1999–2022 30k 20k 503,424


10k Noncommunicable diseases – 81% 0k 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Africa Americas South-East Asia


Western Pacifi c Eastern Mediterranean


Europe Unknown Source: WHO Total number of clinical trial starts by phase, 2014–2023


1,011 4,099


1,538


1,082 4,137


1,618 1,437


4,048 957


1,635 1,456


4,454 952


1,861


2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 1,550


1,641 1,795 2,156 2,150 2,416 2,355 Phase I Phase II Phase III


1,014 4,661


1,852


1,068 5,199


1,975


1,159 5,462


2,153


1,333 6,250


2,501


1,172 5,754


2,227 1,972 1,900


1,001 4,873


Top pharma R&D investment in 2023


Source: Citeline Trialtrove, IQVIA, January 2024.


R&D composite success rate and average phase success rates Phase I to fi ling, 2010–2023


94% 87% 85% 65% 57%


29% 54%


2010 7.5%


52% 27% 88%


64% 57%


38% 88% 74%


66% 56%


63% 58% 52% 37% 37% 24.5% 15.0% 10.5% 2011 Phase success % = 12.2% 12.0% 13.5% 16.1% 11.5% 8.8% 2012 2013 2014 2015 2016


Success (drug reaches any higher phase) Total of success and failure


Composite success % = Phase I x Phase II x Phase III x Regulatory submissions 2017 2018 6.4% 10.8% 6.0% 5.9% 2019 2020 2021 2022 2023


2019–2023 regulatory submission – avg 81%


Phase III – avg 56% Phase II – avg 36%


Composite success – avg 7.6%


Phase I – avg 45% Source: IQVIA Pipeline Intelligence, Dec 2023; IQVIA Institute, January 2024. Clinical Trials Insight / www.worldpharmaceuticals.net Source: Drug Discovery & Development 7 39% 41% 57%


92% 81%


92% 87% 70%


70% 61%


90% 90% 76%


62% 53%


39%


58% 48%


35% 81% 71% 66%


54% 46%


33% 55% 49% 45% 34%


40% 39%


48% 39%


87%


$30.5bn $14.73bn $13.67bn $11.93bn $10.93bn $10.67bn $9.31bn $9.29bn $7.74bn $7.67bn


Communicable, maternal, perinatal and nutritional conditions – 15% Injuries – 4%


Number of trials


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37